Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Working together for success through merger: Aenova and Haupt Pharma

By Pharmaceutical Processing | October 21, 2013

The Aenova Group has announced that it has found in Haupt Pharma, a company specializing in contract development and manufacturing for the pharmaceutical industry, a partner which will help it achieve a strategic expansion of its portfolio. Almost a year after the successful takeover of the Temmler Group, the Aenova Group is increasing its annual turnover by around 60% to nearly $1 Billion USD. The agreement has now been signed, but the purchase price remains confidential. The transaction will go ahead subject to the approval of the relevant competition authorities, but is expected to become legally binding at the end of 2013. 

 

Aenova and Haupt Pharma both have global footprints with strong European foundations and headquarters in Germany. “The strategic activities of both companies complement each other very well and this move gives us further areas of expertise strongly focusing on forward-looking sectors in the pharmaceutical market, which are a perfect fit with our existing portfolio,” said Heiner Hoppmann, CEO of the Aenova Group, commenting on the successful partnership. The merger will add areas such as sterile manufacturing and the production of special active ingredients (including hormones, antibiotics and cytostatics) for the pharmaceutical industry to Aenova’s existing range of solid, semi-solid and liquid dosage forms. The company’s full service portfolio will in future include all the product groups and all the main dosage forms for medicines and dietary supplements. 

 

These new areas of expertise and the expansion of its range of products and services will strengthen the Aenova Group’s market position in the global market. The Aenova Group’s existing production network will increase from eight to twenty-one sites. In addition to new production facilities in Germany (Berlin, Brackenheim, Münster, Gronau, Regensburg, Wolfratshausen) and in Europe, Aenova will also acquire its first site in Asia (Japan). The number of employees will increase from 2,500 to more than 4,000. 

 

The merger of the two companies also offers the ideal opportunity for Haupt Pharma to consolidate and continue the growth that it has experienced over recent years. Otto Prange, chairman of the supervisory board of Haupt Pharma, will continue to accompany the enterprise in the future as co-shareholder of the Aenova Group. As he explained: “The merger will increase our competitiveness in a challenging market and, as a result, make us significantly more attractive to our customers.” 

 

This important transaction is financed with a combination of debt and equity. The debt financing was arranged by IKB, J.P. Morgan and UBS as joint underwriters and bookrunners with the support of RBI, SEB and UniCredit as MLAs and non-physical bookrunners as well as Commerzbank, DZ Bank, GE Capital and Mizuho as MLAs. In addition, IKB and UBS acted as financial advisors to Aenova Group. The equity was essentially provided by funds advised by BC Partners. The investor, which is one of the leading private equity companies, acquired the Aenova Group in August 2012 and has put the group on course for growth.

 

 

 

Aenova Group 

Germany 

www.aenova-group.com

Phone: +49 (0) 8808 9243 126

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE